Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais, Paulo Cesar Ribeiro Barbosa & Lucas Oliveira Maia. (2022) Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey . Substance Use & Misuse 57:7, pages 1072-1081.
Read now
Read now
Zach Walsh & Michelle S. Thiessen. (2018) Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. International Review of Psychiatry 30:4, pages 343-349.
Read now
Read now
Marie Claire Van Hout & Evelyn Hearne. (2015) “Word of Mouse”: Indigenous Harm Reduction and Online Consumerism of the Synthetic Compound Methoxphenidine. Journal of Psychoactive Drugs 47:1, pages 30-41.
Read now
Read now
Anja Loizaga-Velder & Rolf Verres. (2014) Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results. Journal of Psychoactive Drugs 46:1, pages 63-72.
Read now
Read now
EvgenyM. Krupitsky, AndreiM. Burakov, IgorV. Dunaevsky, TatyanaN. Romanova, TatyanaY. Slavina & AlexanderY. Grinenko. (2007) Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence. Journal of Psychoactive Drugs 39:1, pages 13-19.
Read now
Read now
Harris Friedman. (2006) The Renewal of Psychedelic Research: Implications for Humanistic and Transpersonal Psychology. The Humanistic Psychologist 34:1, pages 39-58.
Read now
Read now
Marlene
Dobkin de Rios, CharlesS. Grob & JohnR. Baker. (2002) Hallucinogens and Redemption. Journal of Psychoactive Drugs 34:3, pages 239-248.
Read now
Read now
Ralph Metzner. (1998) Hallucinogenic Drugs and Plants in Psychotherapy and Shamanism. Journal of Psychoactive Drugs 30:4, pages 333-341.
Read now
Read now
Articles from other publishers (43)
Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti & Luís Fernando Tófoli. (2022) Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. Psychopharmacology 239:6, pages 1767-1782.
Crossref
Crossref
Neiloufar Family, Peter S Hendricks, Luke TJ Williams, David Luke, Erwin Krediet, Emeline L Maillet & Shlomi Raz. (2022) Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. Journal of Psychopharmacology 36:3, pages 321-336.
Crossref
Crossref
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer & Felix Betzler. (2021) Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 9:1, pages 48-58.
Crossref
Crossref
David M. O’Shaughnessy, Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai & Frances Quirk. (2021) Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. Therapeutic Advances in Psychopharmacology 11, pages 204512532098663.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira, Carolina Lança Pereira & Diana Dias da Silva. (2019) Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12:3, pages 184-194.
Crossref
Crossref
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett & Roland R. Griffiths. (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197, pages 83-102.
Crossref
Crossref
Nadav Shalit, Jürgen Rehm & Shaul Lev-Ran. (2019) Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III. Addictive Behaviors 89, pages 35-43.
Crossref
Crossref
Tehseen Noorani, Albert Garcia-Romeu, Thomas C Swift, Roland R Griffiths & Matthew W Johnson. (2018) Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology 32:7, pages 756-769.
Crossref
Crossref
Frederic Sampedro, Mario de la Fuente Revenga, Marta Valle, Natalia Roberto, Elisabet Domínguez-Clavé, Matilde Elices, Luís Eduardo Luna, José Alexandre S Crippa, Jaime E C Hallak, Draulio B de Araujo, Pablo Friedlander, Steven A Barker, Enrique Álvarez, Joaquim Soler, Juan C Pascual, Amanda Feilding & Jordi Riba. (2017) Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. International Journal of Neuropsychopharmacology 20:9, pages 698-711.
Crossref
Crossref
Matthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson & Roland R Griffiths. (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology 31:7, pages 841-850.
Crossref
Crossref
Michael P. Bogenschutz & Alyssa A. Forcehimes. (2016) Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology 57:4, pages 389-414.
Crossref
Crossref
Matthew W. Johnson & Roland R. Griffiths. (2017) Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14:3, pages 734-740.
Crossref
Crossref
Piera Talin & Emilia Sanabria. (2017) Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from ‘addiction’. International Journal of Drug Policy 44, pages 23-30.
Crossref
Crossref
Vincent D Pisano, Nathaniel P Putnam, Hannah M Kramer, Kevin J Franciotti, John H Halpern & Selma C Holden. (2017) The association of psychedelic use and opioid use disorders among illicit users in the United States. Journal of Psychopharmacology 31:5, pages 606-613.
Crossref
Crossref
Ben Sessa. (2017) Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?. Journal of Psychedelic Studies 1:1, pages 1-9.
Crossref
Crossref
James W.B. Elsey. (2017) Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Science, Policy and Law 3, pages 205032451772323.
Crossref
Crossref
Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen & Somnath Mondal. (2016) Lysergic acid diethylamide: a drug of ‘use’?. Therapeutic Advances in Psychopharmacology 6:3, pages 214-228.
Crossref
Crossref
Monica F. Tomlinson, Matthew Brown & Peter N.S. Hoaken. (2016) Recreational drug use and human aggressive behavior: A comprehensive review since 2003. Aggression and Violent Behavior 27, pages 9-29.
Crossref
Crossref
Michael P. Bogenschutz & Matthew W. Johnson. (2016) Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 250-258.
Crossref
Crossref
L.F. Tófoli & D.B. de Araujo. 2016. Imaging the Addicted Brain. Imaging the Addicted Brain
157
185
.
Mitchell G. Spring, Rory D. Ostrow & Robert M. Hallock. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
794
800
.
Michael P. Bogenschutz & Stephen Ross. 2018. Behavioral Neurobiology of Psychedelic Drugs. Behavioral Neurobiology of Psychedelic Drugs
361
391
.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, PCR Barbosa & Rick J Strassman. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29:3, pages 289-299.
Crossref
Crossref
Ben Sessa & Matthew W. Johnson. (2018) Can psychedelic compounds play a part in drug dependence
therapy?. British Journal of Psychiatry 206:1, pages 1-3.
Crossref
Crossref
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano & Roland R Griffiths. (2014)
Pilot study of the 5-HT
2A
R agonist psilocybin in the treatment of tobacco addiction
. Journal of Psychopharmacology 28:11, pages 983-992.
Crossref
Crossref
Adam Michael Stewart & Allan V. Kalueff. (2014) The behavioral effects of acute Δ9-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish. Brain Research 1543, pages 109-119.
Crossref
Crossref
Michael J. Winkelman. 2014. The Therapeutic Use of Ayahuasca. The Therapeutic Use of Ayahuasca
1
21
.
Marcelo S. Mercante. (2013) A ayahuasca e o tratamento da dependência. Mana 19:3, pages 529-558.
Crossref
Crossref
Michael P. Bogenschutz & Jessica M. Pommy. (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Testing and Analysis 4:7-8, pages 543-555.
Crossref
Crossref
Evan J. Kyzar, Christopher Collins, Siddharth Gaikwad, Jeremy Green, Andrew Roth, Louie Monnig, Mohamed El-Ounsi, Ari Davis, Andrew Freeman, Nicholas Capezio, Adam Michael Stewart & Allan V. Kalueff. (2012) Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology. Progress in Neuro-Psychopharmacology and Biological Psychiatry 37:1, pages 194-202.
Crossref
Crossref
Katherine A MacLeanMatthew W JohnsonRoland R Griffiths. (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 25:11, pages 1453-1461.
Crossref
Crossref
James Rodger. (2011) The visionary cure of the addiction war? Ibogaine: social context, subcultural identity, and implications for drug policy. Drugs and Alcohol Today 11:2, pages 77-89.
Crossref
Crossref
Vibeke S. Catts & Stanley V. Catts. 2011. Secondary Schizophrenia. Secondary Schizophrenia
141
168
.
Marcelo S. Mercante. (2009) Ayahuasca, dependência química e alcoolismo. Ponto Urbe:5.
Crossref
Crossref
MW Johnson, WA Richards & RR Griffiths. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22:6, pages 603-620.
Crossref
Crossref
John H. Halpern, Andrea R. Sherwood, James I. Hudson, Deborah Yurgelun-Todd & Harrison G. PopeJrJr. (2005) Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans. Biological Psychiatry 58:8, pages 624-631.
Crossref
Crossref
John H Halpern. (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology & Therapeutics 102:2, pages 131-138.
Crossref
Crossref
David E Nichols. (2004) Hallucinogens. Pharmacology & Therapeutics 101:2, pages 131-181.
Crossref
Crossref
John H. Halpern. (2003) Hallucinogens: An update. Current Psychiatry Reports 5:5, pages 347-354.
Crossref
Crossref
Evgeny Krupitsky, Andrey Burakov, Tatyana Romanova, Igor Dunaevsky, Rick Strassman & Alexander Grinenko. (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23:4, pages 273-283.
Crossref
Crossref
Joseph D. Calabrese. (2008) The Supreme Court versus Peyote: Consciousness Alteration, Cultural Psychiatry and the Dilemma of Contemporary Subcultures. Anthropology of Consciousness 12:2, pages 4-18.
Crossref
Crossref
Scott Helsley, Richard A Rabin & J.C Winter. 2001.
63
77
.
Scott Helsley, Richard A. Rabin & Jerrold C. Winter. (1999) Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. Progress in Neuro-Psychopharmacology and Biological Psychiatry 23:2, pages 317-326.
Crossref
Crossref